2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
The dedicated US HCM guideline — the ESC covers HCM inside its 2023 cardiomyopathy document — and it was reaffirmed as current in May 2025. It gives cardiac myosin inhibitors a formal place in symptomatic obstructive HCM on the strength of EXPLORER-HCM and VALOR-HCM, and it loosens the old blanket restriction on vigorous exercise, which now becomes a shared decision rather than a prohibition. The most persistent transatlantic difference is sudden-death risk stratification: the ACC/AHA works from a set of individual major risk markers plus imaging (apical aneurysm, extensive late gadolinium enhancement), while the ESC calculates the HCM Risk-SCD five-year probability — the two approaches select overlapping but not identical patients for an ICD. The register's HCM trials are grouped below.
This guideline cites 3 of the 199 landmark trials in our Cardiology register.
Cardiac myosin inhibitors — obstructive HCM2
- 2022VALOR-HCMCardiology · HF · myosin inhibitorA Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy
- 2020EXPLORER-HCMCardiology · HF · myosin inhibitorClinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Exercise & physical activity1
- 2017RESET-HCMCardiology · HF · Exercise in cardiomyopathyRandomised Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy
Published since the guideline1
- 2024SEQUOIA-HCMCardiology · HF · myosin inhibitorSafety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM